Founded in 2012 and headquartered in Geneva, Switzerland, ObsEva SA (formerly Nasdaq: OBSV) was a biopharmaceutical company focused on developing and commercializing novel therapies for conditions in women's reproductive health and pregnancy. The company's pipeline included linzagolix (GnRH receptor antagonist for uterine fibroids and endometriosis) and ebopiprant (for preterm labor). ObsEva completed an IPO in 2018. Due to financial difficulties, the company undertook a strategic reorganization in 2023 and ultimately wound down operations and laid off all employees in February 2024.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2020
Jan 2017
Nov 2015
Aug 2013
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
